$NVCR Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NovoCure Ltd.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in NovoCure Ltd. Get notifications about new insider transactions in NovoCure Ltd for free.
Page: < prev 1 ... 4 5 6 7 8 9 10 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 03 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 27.40 | 60,000 | 1,644,000 | 146,558 | 206.6 K to 146.6 K (-29.05 %) |
| May 03 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | M | 7.03 | 31,305 | 220,074 | 206,558 | 237.9 K to 206.6 K (-13.16 %) |
| May 03 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 3.44 | 28,695 | 98,711 | 175,253 | 146.6 K to 175.3 K (+19.58 %) |
| Apr 30 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 3.44 | 20,000 | 68,800 | 28,695 | |
| Apr 30 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 26.05 | 328 | 8,544 | 146,558 | 146.9 K to 146.6 K (-0.22 %) |
| Apr 30 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 26.03 | 4,300 | 111,908 | 146,886 | 151.2 K to 146.9 K (-2.84 %) |
| Apr 30 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 26.01 | 1,800 | 46,818 | 151,186 | 153 K to 151.2 K (-1.18 %) |
| Apr 30 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 26.00 | 13,572 | 352,872 | 152,986 | 166.6 K to 153 K (-8.15 %) |
| Apr 30 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 3.44 | 20,000 | 68,800 | 166,558 | 146.6 K to 166.6 K (+13.65 %) |
| Apr 25 2018 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 25.06 | 5,600 | 140,320 | 1,182,020 | 1.2 M to 1.2 M (-0.47 %) |
| Apr 25 2018 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 25.07 | 30,000 | 751,962 | 1,187,620 | 1.2 M to 1.2 M (-2.46 %) |
| Apr 23 2018 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 25.06 | 19,362 | 485,183 | 1,217,620 | 1.2 M to 1.2 M (-1.57 %) |
| Apr 23 2018 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 25.06 | 16,081 | 402,990 | 1,236,982 | 1.3 M to 1.2 M (-1.28 %) |
| Apr 23 2018 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 24.79 | 13,919 | 345,052 | 1,253,063 | 1.3 M to 1.3 M (-1.10 %) |
| Apr 20 2018 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Option Exercise | M | 3.44 | 70,956 | 244,089 | 0 | |
| Apr 20 2018 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Option Exercise | M | 3.44 | 76,869 | 264,429 | 0 | |
| Apr 20 2018 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | S | 24.00 | 70,956 | 1,702,944 | 39,582 | 110.5 K to 39.6 K (-64.19 %) |
| Apr 20 2018 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Buy | M | 3.44 | 70,956 | 244,089 | 110,538 | 39.6 K to 110.5 K (+179.26 %) |
| Apr 20 2018 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | S | 24.00 | 76,869 | 1,844,856 | 39,582 | 116.5 K to 39.6 K (-66.01 %) |
| Apr 20 2018 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Buy | M | 3.44 | 76,869 | 264,429 | 116,451 | 39.6 K to 116.5 K (+194.20 %) |
| Apr 19 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 3.44 | 20,000 | 68,800 | 48,695 | |
| Apr 19 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 3.44 | 20,000 | 68,800 | 68,695 | |
| Apr 19 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 24.00 | 20,000 | 480,000 | 146,558 | 166.6 K to 146.6 K (-12.01 %) |
| Apr 19 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 3.44 | 20,000 | 68,800 | 166,558 | 146.6 K to 166.6 K (+13.65 %) |
| Apr 19 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 22.21 | 545 | 12,104 | 146,558 | 147.1 K to 146.6 K (-0.37 %) |
| Apr 19 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 22.10 | 1,255 | 27,741 | 147,103 | 148.4 K to 147.1 K (-0.85 %) |
| Apr 19 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 22.10 | 2,000 | 44,200 | 148,358 | 150.4 K to 148.4 K (-1.33 %) |
| Apr 19 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 22.05 | 15,900 | 350,595 | 150,358 | 166.3 K to 150.4 K (-9.56 %) |
| Apr 19 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 22.00 | 300 | 6,600 | 166,258 | 166.6 K to 166.3 K (-0.18 %) |
| Apr 19 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 3.44 | 20,000 | 68,800 | 166,558 | 146.6 K to 166.6 K (+13.65 %) |
| Apr 19 2018 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 24.10 | 14,072 | 339,080 | 1,266,982 | 1.3 M to 1.3 M (-1.10 %) |
| Apr 19 2018 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 23.44 | 30,000 | 703,224 | 1,281,054 | 1.3 M to 1.3 M (-2.29 %) |
| Apr 05 2018 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 19.89 | 30,000 | 596,754 | 1,311,054 | 1.3 M to 1.3 M (-2.24 %) |
| Apr 04 2018 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 20.23 | 26,300 | 532,049 | 1,341,054 | 1.4 M to 1.3 M (-1.92 %) |
| Apr 04 2018 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 19.87 | 3,700 | 73,519 | 1,367,354 | 1.4 M to 1.4 M (-0.27 %) |
| Apr 04 2018 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 20.38 | 27,489 | 560,226 | 1,371,054 | 1.4 M to 1.4 M (-1.97 %) |
| Apr 04 2018 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 21.36 | 2,511 | 53,635 | 1,398,543 | 1.4 M to 1.4 M (-0.18 %) |
| Apr 02 2018 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 22.00 | 4,300 | 94,600 | 1,401,054 | 1.4 M to 1.4 M (-0.31 %) |
| Apr 02 2018 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 21.61 | 25,700 | 555,377 | 1,405,354 | 1.4 M to 1.4 M (-1.80 %) |
| Mar 20 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 0.23 | 49,728 | 11,437 | 0 | |
| Mar 20 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 0.23 | 49,728 | 11,437 | 146,558 | 96.8 K to 146.6 K (+51.36 %) |
| Mar 01 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | A | 0.00 | 16,667 | 0 | 16,667 | |
| Mar 01 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | A | 21.15 | 121,655 | 2,573,003 | 121,655 | |
| Mar 01 2018 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Option Exercise | A | 0.00 | 20,833 | 0 | 20,833 | |
| Mar 01 2018 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Option Exercise | A | 21.15 | 152,068 | 3,216,238 | 152,068 | |
| Mar 01 2018 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | A | 0.00 | 27,778 | 0 | 27,778 | |
| Mar 01 2018 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | A | 21.15 | 202,758 | 4,288,332 | 202,758 | |
| Mar 01 2018 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Option Exercise | A | 0.00 | 27,778 | 0 | 27,778 | |
| Mar 01 2018 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Option Exercise | A | 21.15 | 202,758 | 4,288,332 | 202,758 | |
| Mar 01 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | A | 0.00 | 18,519 | 0 | 18,519 | |
| Mar 01 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | A | 21.15 | 135,172 | 2,858,888 | 135,172 | |
| Feb 26 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 0.00 | 21,667 | 0 | 43,333 | |
| Feb 26 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 19.83 | 6,591 | 130,686 | 20,074 | 26.7 K to 20.1 K (-24.72 %) |
| Feb 26 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 21.55 | 21,667 | 466,924 | 26,665 | 5 K to 26.7 K (+433.51 %) |
| Feb 26 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 0.00 | 31,201 | 0 | 62,399 | |
| Feb 26 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 19.83 | 8,458 | 167,705 | 96,830 | 105.3 K to 96.8 K (-8.03 %) |
| Feb 26 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 21.55 | 31,201 | 672,382 | 105,288 | 74.1 K to 105.3 K (+42.11 %) |
| Feb 26 2018 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Option Exercise | M | 0.00 | 53,334 | 0 | 106,666 | |
| Feb 26 2018 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Buy | M | 21.55 | 53,334 | 1,149,348 | 410,124 | 356.8 K to 410.1 K (+14.95 %) |
| Feb 26 2018 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Option Exercise | M | 0.00 | 36,401 | 0 | 72,799 | |
| Feb 26 2018 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Buy | M | 21.55 | 36,401 | 784,442 | 39,582 | 3.2 K to 39.6 K (+1,144.33 %) |
| Feb 26 2018 | NVCR | Novocure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 0.00 | 43,334 | 0 | 86,666 | |
| Feb 26 2018 | NVCR | Novocure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 19.83 | 13,351 | 264,724 | 239,061 | 252.4 K to 239.1 K (-5.29 %) |
| Feb 26 2018 | NVCR | Novocure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 21.55 | 43,334 | 933,848 | 252,412 | 209.1 K to 252.4 K (+20.73 %) |
| Feb 08 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 0.23 | 50,000 | 11,500 | 74,087 | |
| Feb 08 2018 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 0.23 | 50,000 | 11,500 | 74,087 | 24.1 K to 74.1 K (+207.58 %) |
| Jan 31 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 6.72 | 11,630 | 78,154 | 71,152 | |
| Jan 31 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 24.00 | 11,630 | 279,120 | 4,998 | 16.6 K to 5 K (-69.94 %) |
| Jan 31 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 6.72 | 11,630 | 78,154 | 16,628 | 5 K to 16.6 K (+232.69 %) |
| Jan 31 2018 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 24.02 | 13,974 | 335,588 | 356,790 | 370.8 K to 356.8 K (-3.77 %) |
| Jan 26 2018 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 22.43 | 6,456 | 144,840 | 370,764 | 377.2 K to 370.8 K (-1.71 %) |
| Jan 25 2018 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 22.17 | 10,600 | 235,007 | 377,220 | 387.8 K to 377.2 K (-2.73 %) |
| Jan 25 2018 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 22.03 | 10,248 | 225,794 | 387,820 | 398.1 K to 387.8 K (-2.57 %) |
| Jan 24 2018 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 3.59 | 1,549 | 5,561 | 0 | |
| Jan 24 2018 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 3.59 | 1,549 | 5,561 | 92,746 | 91.2 K to 92.7 K (+1.70 %) |
| Jan 17 2018 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 22.20 | 14,900 | 330,755 | 398,068 | 413 K to 398.1 K (-3.61 %) |
| Jan 16 2018 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | S | 22.00 | 25,320 | 557,126 | 3,181 | 28.5 K to 3.2 K (-88.84 %) |
| Jan 16 2018 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 22.02 | 22,895 | 504,237 | 412,968 | 435.9 K to 413 K (-5.25 %) |
| Jan 16 2018 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 22.35 | 313,525 | 7,007,503 | 435,863 | 749.4 K to 435.9 K (-41.84 %) |
| Jan 10 2018 | NVCR | Novocure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 21.02 | 31,132 | 654,376 | 209,078 | 240.2 K to 209.1 K (-12.96 %) |
| Jan 10 2018 | NVCR | Novocure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Grant | A | 15.05 | 310 | 4,664 | 240,210 | 239.9 K to 240.2 K (+0.13 %) |
| Jan 10 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Grant | A | 15.05 | 166 | 2,497 | 4,998 | 4.8 K to 5 K (+3.44 %) |
| Jan 10 2018 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Grant | A | 15.05 | 283 | 4,258 | 749,388 | 749.1 K to 749.4 K (+0.04 %) |
| Jan 05 2018 | NVCR | Novocure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 21.03 | 26,264 | 552,314 | 239,900 | 266.2 K to 239.9 K (-9.87 %) |
| Jan 05 2018 | NVCR | Novocure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 21.00 | 2,404 | 50,484 | 266,164 | 268.6 K to 266.2 K (-0.90 %) |
| Jan 05 2018 | NVCR | Novocure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 21.03 | 200 | 4,205 | 268,568 | 268.8 K to 268.6 K (-0.07 %) |
| Nov 14 2017 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 17.13 | 30,000 | 513,870 | 1,431,054 | 1.5 M to 1.4 M (-2.05 %) |
| Nov 13 2017 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 18.04 | 3,900 | 70,356 | 1,461,054 | 1.5 M to 1.5 M (-0.27 %) |
| Nov 13 2017 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 17.54 | 26,100 | 457,794 | 1,464,954 | 1.5 M to 1.5 M (-1.75 %) |
| Nov 13 2017 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 18.74 | 5,388 | 100,971 | 1,491,054 | 1.5 M to 1.5 M (-0.36 %) |
| Nov 13 2017 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 18.14 | 24,612 | 446,462 | 1,496,442 | 1.5 M to 1.5 M (-1.62 %) |
| Nov 13 2017 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 20.17 | 6,266 | 126,385 | 1,521,054 | 1.5 M to 1.5 M (-0.41 %) |
| Nov 13 2017 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 19.46 | 23,734 | 461,864 | 1,527,320 | 1.6 M to 1.5 M (-1.53 %) |
| Nov 08 2017 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 21.14 | 2,900 | 61,306 | 1,551,054 | 1.6 M to 1.6 M (-0.19 %) |
| Nov 08 2017 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 20.34 | 27,100 | 551,214 | 1,553,954 | 1.6 M to 1.6 M (-1.71 %) |
| Nov 08 2017 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 21.71 | 30,000 | 651,240 | 1,581,054 | 1.6 M to 1.6 M (-1.86 %) |
| Nov 08 2017 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | S | 22.00 | 9,100 | 200,200 | 28,501 | 37.6 K to 28.5 K (-24.20 %) |
| Nov 08 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 22.00 | 6,919 | 152,218 | 749,105 | 756 K to 749.1 K (-0.92 %) |
| Nov 06 2017 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 21.66 | 30,000 | 649,680 | 1,611,054 | 1.6 M to 1.6 M (-1.83 %) |
| Nov 06 2017 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 21.78 | 30,000 | 653,520 | 1,641,054 | 1.7 M to 1.6 M (-1.80 %) |
| Nov 06 2017 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | S | 22.00 | 3,100 | 68,200 | 37,601 | 40.7 K to 37.6 K (-7.62 %) |
| Nov 06 2017 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | S | 22.00 | 300 | 6,600 | 40,701 | 41 K to 40.7 K (-0.73 %) |
| Nov 06 2017 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 22.00 | 900 | 19,800 | 24,087 | 25 K to 24.1 K (-3.60 %) |
| Nov 06 2017 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 22.00 | 300 | 6,600 | 24,987 | 25.3 K to 25 K (-1.19 %) |
| Nov 06 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 22.00 | 2,300 | 50,600 | 756,024 | 758.3 K to 756 K (-0.30 %) |
| Nov 02 2017 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 22.01 | 24,227 | 533,164 | 25,287 | 49.5 K to 25.3 K (-48.93 %) |
| Nov 02 2017 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 22.00 | 100 | 2,200 | 49,514 | 49.6 K to 49.5 K (-0.20 %) |
| Sep 27 2017 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | D | 22.03 | 1,900 | 41,865 | 63,270 | 65.2 K to 63.3 K (-2.92 %) |
| Sep 27 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 22.05 | 900 | 19,845 | 774,190 | 775.1 K to 774.2 K (-0.12 %) |
| Sep 27 2017 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | D | 22.05 | 3,200 | 70,555 | 49,614 | 52.8 K to 49.6 K (-6.06 %) |
| Sep 21 2017 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | D | 22.00 | 3,200 | 70,400 | 52,814 | 56 K to 52.8 K (-5.71 %) |
| Sep 15 2017 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | D | 22.03 | 2,500 | 55,080 | 65,170 | 67.7 K to 65.2 K (-3.69 %) |
| Sep 15 2017 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | D | 22.01 | 46,872 | 1,031,765 | 67,670 | 114.5 K to 67.7 K (-40.92 %) |
| Sep 15 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 22.00 | 1,772 | 38,984 | 775,090 | 776.9 K to 775.1 K (-0.23 %) |
| Sep 15 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 22.01 | 35,500 | 781,518 | 776,862 | 812.4 K to 776.9 K (-4.37 %) |
| Sep 15 2017 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | D | 22.00 | 1,746 | 38,417 | 56,014 | 57.8 K to 56 K (-3.02 %) |
| Sep 15 2017 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | D | 22.02 | 76,327 | 1,680,522 | 57,760 | 134.1 K to 57.8 K (-56.92 %) |
| Jul 18 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Option Exercise | M | 0.38 | 354,780 | 134,816 | 0 | |
| Jul 18 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Buy | M | 0.38 | 354,780 | 134,816 | 812,362 | 457.6 K to 812.4 K (+77.53 %) |
| Jul 13 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 20.19 | 5,183 | 104,645 | 457,582 | 462.8 K to 457.6 K (-1.12 %) |
| Jul 13 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 19.40 | 2,200 | 42,680 | 462,765 | 465 K to 462.8 K (-0.47 %) |
| Jul 11 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 18.08 | 203,900 | 3,685,900 | 464,965 | 668.9 K to 465 K (-30.48 %) |
| Jul 11 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 18.03 | 70,459 | 1,270,658 | 668,865 | 739.3 K to 668.9 K (-9.53 %) |
| Jul 07 2017 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Grant | A | 6.67 | 2,810 | 18,751 | 4,832 | 2 K to 4.8 K (+138.97 %) |
| Jul 07 2017 | NVCR | Novocure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Grant | A | 6.67 | 2,484 | 16,576 | 268,768 | 266.3 K to 268.8 K (+0.93 %) |
| Jul 07 2017 | NVCR | Novocure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Grant | A | 6.67 | 1,395 | 9,309 | 134,087 | 132.7 K to 134.1 K (+1.05 %) |
| Jul 07 2017 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | D | 18.14 | 111,361 | 2,020,534 | 114,542 | 225.9 K to 114.5 K (-49.30 %) |
| Jul 07 2017 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Grant | A | 6.67 | 3,181 | 21,227 | 225,903 | 222.7 K to 225.9 K (+1.43 %) |
| Jul 07 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 18.09 | 5,050 | 91,344 | 739,324 | 744.4 K to 739.3 K (-0.68 %) |
| Jul 07 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 18.14 | 155,088 | 2,813,917 | 744,374 | 899.5 K to 744.4 K (-17.24 %) |
| Jul 07 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Grant | A | 6.67 | 2,545 | 16,983 | 899,462 | 896.9 K to 899.5 K (+0.28 %) |
| Jun 27 2017 | NVCR | Novocure Ltd | Pomona Capital VII, L.P. | 10% Owner | Sell | S | 17.46 | 30,945 | 540,204 | 2,741,925 | 2.8 M to 2.7 M (-1.12 %) |
| Jun 27 2017 | NVCR | Novocure Ltd | Pomona Capital VII, L.P. | 10% Owner | Sell | S | 17.46 | 68,396 | 1,193,982 | 6,060,403 | 6.1 M to 6.1 M (-1.12 %) |
| Jun 27 2017 | NVCR | Novocure Ltd | Pomona Capital VII, L.P. | 10% Owner | Sell | S | 17.34 | 303,149 | 5,255,906 | 2,772,870 | 3.1 M to 2.8 M (-9.86 %) |
| Jun 27 2017 | NVCR | Novocure Ltd | Pomona Capital VII, L.P. | 10% Owner | Sell | S | 17.34 | 670,042 | 11,616,987 | 6,128,799 | 6.8 M to 6.1 M (-9.86 %) |
| Jun 22 2017 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | S | 16.78 | 66,361 | 1,113,206 | 222,722 | 289.1 K to 222.7 K (-22.96 %) |
| Jun 21 2017 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | S | 15.06 | 15,000 | 225,885 | 289,083 | 304.1 K to 289.1 K (-4.93 %) |
| Jun 21 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 15.51 | 124,720 | 1,934,906 | 896,917 | 1 M to 896.9 K (-12.21 %) |
| Jun 19 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 15.02 | 9,212 | 138,346 | 1,021,637 | 1 M to 1 M (-0.89 %) |
| Jun 19 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 15.19 | 33,245 | 504,892 | 1,030,849 | 1.1 M to 1 M (-3.12 %) |
| Jun 15 2017 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | S | 15.01 | 9,044 | 135,769 | 304,083 | 313.1 K to 304.1 K (-2.89 %) |
| Jun 15 2017 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Director | Option Exercise | M | 3.59 | 6,498 | 23,328 | 0 | |
| Jun 15 2017 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Director | Buy | M | 3.59 | 6,498 | 23,328 | 91,197 | 84.7 K to 91.2 K (+7.67 %) |
| Jun 15 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 15.01 | 5,402 | 81,068 | 1,064,094 | 1.1 M to 1.1 M (-0.51 %) |
| Jun 15 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 15.23 | 88,700 | 1,351,078 | 1,069,496 | 1.2 M to 1.1 M (-7.66 %) |
| Jun 13 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 15.09 | 5,100 | 76,934 | 1,158,196 | 1.2 M to 1.2 M (-0.44 %) |
| Jun 13 2017 | NVCR | Novocure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 15.13 | 175,501 | 2,654,979 | 1,163,296 | 1.3 M to 1.2 M (-13.11 %) |
| Jun 13 2017 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | S | 15.08 | 5,956 | 89,828 | 313,127 | 319.1 K to 313.1 K (-1.87 %) |
| Jun 13 2017 | NVCR | Novocure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | S | 15.02 | 15,000 | 225,225 | 319,083 | 334.1 K to 319.1 K (-4.49 %) |
| Jun 06 2017 | NVCR | Novocure Ltd | Palti Yoram | Chief Technology Of ... | Sell | S | 13.82 | 3,825 | 52,842 | 0 | 3.8 K to 0 (-100.00 %) |